Literature DB >> 11511553

Inverse background of Helicobacter pylori antibody and pepsinogen in reflux oesophagitis compared with gastric cancer: analysis of 5732 Japanese subjects.

Y Yamaji1, T Mitsushima, H Ikuma, M Okamoto, H Yoshida, T Kawabe, Y Shiratori, K Saito, K Yokouchi, M Omata.   

Abstract

BACKGROUND: The relationship between Helicobacter pylori and reflux oesophagitis remains controversial. AIMS: To evaluate the relationship between H pylori and reflux oesophagitis in a large number of Japanese subjects.
SUBJECTS: A total of 5732 consecutive Japanese subjects during a health screening were enrolled.
METHODS: Gastrointestinal endoscopy was performed on all subjects. We simultaneously measured serum anti-H pylori antibody and pepsinogen as markers of H pylori infection together with gastric atrophy. The risk of reflux oesophagitis was evaluated in relation to these markers, and the results were compared with those of gastric cancer.
RESULTS: Reflux oesophagitis was found in 108 subjects. Both positivity for H pylori antibody (adjusted odds ratio (OR) 0.67 (95% confidence interval 0.45-1.0)) and "low" pepsinogen indicating gastric atrophy (OR 0.35 (0.18-0.68)) were negatively associated with reflux oesophagitis. After subjects were classified into four groups based on positivity or negativity for H pylori antibody and "low" pepsinogen, the prevalence of reflux oesophagitis showed a decreasing trend as H pylori induced gastric atrophy became more severe. The risk of gastric cancer showed an increasing trend, exactly the opposite to that of reflux oesophagitis.
CONCLUSIONS: Analysis of a large series of Japanese subjects revealed a decreasing prevalence of reflux oesophagitis in conjunction with progress of gastric atrophy induced by H pylori infection. This pattern was completely opposite to that of gastric cancer cases. A protective role of H pylori for reflux oesophagitis through the development of gastric atrophy has been suggested.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11511553      PMCID: PMC1728449          DOI: 10.1136/gut.49.3.335

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  47 in total

1.  Helicobacter pylori gastritis and gastric MALT-lymphoma.

Authors:  M Stolte
Journal:  Lancet       Date:  1992-03-21       Impact factor: 79.321

2.  Serum pepsinogens as a screening test of extensive chronic gastritis.

Authors:  K Miki; M Ichinose; A Shimizu; S C Huang; H Oka; C Furihata; T Matsushima; K Takahashi
Journal:  Gastroenterol Jpn       Date:  1987-04

3.  Serum pepsinogens I and II and gastric acid output: effect of gastritis.

Authors:  I M Samloff; K Varis; T Ihamäki; M Siurala; J I Rotter
Journal:  Prog Clin Biol Res       Date:  1985

4.  Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia.

Authors:  I M Samloff; K Varis; T Ihamaki; M Siurala; J I Rotter
Journal:  Gastroenterology       Date:  1982-07       Impact factor: 22.682

5.  Prevalence of Campylobacter pylori in esophagitis, gastritis, and duodenal disease.

Authors:  E H Cheng; P Bermanski; M Silversmith; P Valenstein; H Kawanishi
Journal:  Arch Intern Med       Date:  1989-06

6.  Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis.

Authors:  W E Karnes; I M Samloff; M Siurala; M Kekki; P Sipponen; S W Kim; J H Walsh
Journal:  Gastroenterology       Date:  1991-07       Impact factor: 22.682

7.  Clinical significance of pepsinogen A isozymogens, serum pepsinogen A and C levels, and serum gastrin levels.

Authors:  B D Westerveld; G Pals; C B Lamers; J Defize; J C Pronk; R R Frants; E C Ooms; J Kreuning; P J Kostense; A W Eriksson
Journal:  Cancer       Date:  1987-03-01       Impact factor: 6.860

8.  Serum pepsinogen I and serum gastrin in the screening of severe atrophic corpus gastritis.

Authors:  M Kekki; I M Samloff; K Varis; T Ihamäki
Journal:  Scand J Gastroenterol Suppl       Date:  1991

9.  Treatment of ulcerative reflux oesophagitis with colloidal bismuth subcitrate in combination with cimetidine.

Authors:  M V Borkent; J A Beker
Journal:  Gut       Date:  1988-03       Impact factor: 23.059

10.  Rising incidence of adenocarcinoma of the esophagus and gastric cardia.

Authors:  W J Blot; S S Devesa; R W Kneller; J F Fraumeni
Journal:  JAMA       Date:  1991-03-13       Impact factor: 56.272

View more
  34 in total

1.  The new modified ABCD method for gastric neoplasm screening.

Authors:  Chan Hyuk Park; Eun Hye Kim; Da Hyun Jung; Hyunsoo Chung; Jun Chul Park; Sung Kwan Shin; Sang Kil Lee; Yong Chan Lee
Journal:  Gastric Cancer       Date:  2015-02-08       Impact factor: 7.370

Review 2.  The interplay between Helicobacter pylori, gastro-oesophageal reflux disease, and intestinal metaplasia.

Authors:  P Malfertheiner; U Peitz
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

3.  Gastric atrophy and xanthelasma are markers for predicting the development of early gastric cancer.

Authors:  Akira Sekikawa; Hirokazu Fukui; Ryota Sada; Manabu Fukuhara; Saiko Marui; Gensho Tanke; Masatsugu Endo; Yoshiaki Ohara; Fumihiro Matsuda; Jun Nakajima; Shinichiro Henmi; Sumio Saito; Takehiko Tsumura; Takanori Maruo; Toru Kimura; Yukio Osaki
Journal:  J Gastroenterol       Date:  2015-04-23       Impact factor: 7.527

4.  Inflammation as a cardiovascular risk factor and pulse wave velocity as a marker of early-stage atherosclerosis in the Japanese population.

Authors:  Yasuaki Saijo; Megumi Utsugi; Eiji Yoshioka; Tomonori Fukui; Fumihiro Sata; Naoki Nakagawa; Naoyuki Hasebe; Takahiko Yoshida; Reiko Kishi
Journal:  Environ Health Prev Med       Date:  2009-03-17       Impact factor: 3.674

5.  Randomized controlled trial comparing gastric cancer screening by gastrointestinal X-ray with serology for Helicobacter pylori and pepsinogens followed by gastrointestinal endoscopy.

Authors:  Takuji Gotoda; Hideki Ishikawa; Hirohide Ohnishi; Kentaro Sugano; Chika Kusano; Chizu Yokoi; Yutaka Matsuyama; Fuminori Moriyasu
Journal:  Gastric Cancer       Date:  2014-08-13       Impact factor: 7.370

6.  Assessment of gastroesophageal reflux disease by serodiagnosis of Helicobacter pylori-related chronic gastritis stage.

Authors:  Shotaro Enomoto; Masashi Oka; Hiroshi Ohata; Chizu Mukoubayashi; Mika Watanabe; Kosaku Moribata; Yosuke Muraki; Naoki Shingaki; Hisanobu Deguchi; Kazuki Ueda; Izumi Inoue; Takao Maekita; Mikitaka Iguchi; Kimihiko Yanaoka; Hideyuki Tamai; Mitsuhiro Fujishiro; Osamu Mohara; Masao Ichinose
Journal:  World J Gastrointest Endosc       Date:  2011-04-16

7.  Gastric acid normosecretion is not essential in the pathogenesis of mild erosive gastroesophageal reflux disease in relation to Helicobacter pylori status.

Authors:  Tomohiko Shimatani; Masaki Inoue; Nobue Harada; Yoko Horikawa; Masuo Nakamura; Susumu Tazuma
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

8.  Alteration of correlation between serum pepsinogen concentrations and gastric acid secretion after H. pylori eradication.

Authors:  Katsunori Iijima; Tomoyuki Koike; Yasuhiko Abe; Nobuyuki Ara; Kaname Uno; Akira Imatani; Shuichi Ohara; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2009-05-14       Impact factor: 7.527

9.  Study of association between atrophic gastritis and body mass index: a cross-sectional study in 10,197 Japanese subjects.

Authors:  Hirotsugu Watabe; Toru Mitsushima; Mohammad H Derakhshan; Yutaka Yamaji; Makoto Okamoto; Takao Kawabe; Masao Omata; Kenneth E L McColl
Journal:  Dig Dis Sci       Date:  2008-09-12       Impact factor: 3.199

10.  Helicobacter pylori eradication does not exacerbate gastro-oesophageal reflux disease.

Authors:  P Malfertheiner
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.